In the search for vaccines against the coronavirus, the biotechnology research and development (R&D) sector has attracted a great deal of public attention and set financing records over the past two years in the form of venture capital, IPOs and convertible bonds. Accordingly, turnover and expenditure on R&D by German biotechnology companies have risen significantly. However, sentiment has deteriorated over the past two years. In addition to high energy costs, the shortage of skilled labour and a decreasing number of financing options are slowing down the business situation and sales development of companies in the sector. In 2022, only a third of the amount of equity from 2020 was raised. In 2023, venture capital, which is raised in the early phase at the start of a business start-up, fell by a third. In contrast, capital raised has improved again overall.The industry recorded an average annual growth rate of 3.2% between 2019 and 2024. In the current year, industry turnover is expected to amount to 3.1 billion euros. This corresponds to an increase in turnover of 2.8% compared to the previous year. Investments are currently particularly high in companies specialising in cancer therapies. However, biotechnology companies focussing on nutritional and industrial topics are also able to conclude large financing rounds.However, the difficult recruitment situation and the negative trend in R&D investments are likely to continue. Only a third of companies are planning to invest more in R&D this year. This development shows that companies have started the new year with great uncertainty despite positive sales development, and the current political climate for biotechnology companies is rated correspondingly poorly.Over the next five years, IBISWorld expects industry turnover to increase at an average annual growth rate of 5.6% and is expected to reach 4.1 billion euros in 2029. In addition to the medical sector, industry players also see great growth potential in agricultural biotechnology and industrial biotechnology. Solutions for sustainable industrial production as well as environmental, energy and nutritional issues could generate significant sales in the coming years. There are also great opportunities in the field of artificial intelligence. This makes the calls from politicians to strengthen Germany as a business location in the long term and, for example, to create framework conditions that also make financing attractive for smaller companies all the louder.

Germany Biotechnology Market was valued at USD 35.30 Billion in 2024 and is projected to reach USD 248.8 Billion by 2032, growing at a CAGR of 15.6% from 2026 to 2032.Increased Healthcare Digitalization - Integration of AI and digital technologies in drug discovery and diagnostics is accelerating development timelines and improving precision medicine capabilities across German biotech firms.Government Support for Bioeconomy Initiatives - Federal investment of over €1.08 billion in 2023 and policy frameworks promoting sustainable biotechnology solutions are creating favorable conditions for industry expansion and innovation.

The Germany biotechnology market was valued at USD 35.30 Billion in 2024, driven by the strong public and private investment in biotech innovation and R&D, supported by well-established academic and research institutions across the region. The market is anticipated to grow at a CAGR of 10.30% during the forecast period of 2025-2034, with the values likely to reach USD 94.09 Billion by 2034. Favorable government initiatives and funding accelerate the development and commercialization of advanced biotechnological solutions. The market growth is also characterized by robust infrastructure, high R&D capacity, and a skilled workforce. Increasing adoption of precision medicine and biopharmaceuticals will support growth in the forecast period.

Germany's Agriculture Biotechnology market poised for over 5% CAGR (2024-2029), driven by increasing adoption of advanced biotech solutions.

In 2024, the pharmaceutical company Novo Nordisk was the German biotech and pharmaceutical company with the largest market capitalization of *** billion dollars. In second place was Merck & Co Inc with a capitalization of *** billion dollars.

Snapshot img

Biotech Market Size 2025-2029

The biotech market size is forecast to increase by USD 805.6 billion at a CAGR of 12.4% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing innovation and investment from market companies. These companies are expanding their research and development efforts to bring new products and technologies to market, addressing unmet medical needs and advancing scientific discoveries. However, this growth comes with challenges, primarily regulatory compliance. Stringent regulations governing the biotech industry ensure the safety and efficacy of products, but they also add costs and complexity to the development process. Biologics, comprised of monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies, are derived from living organisms and cater to the treatment of numerous diseases, such as cancer, autoimmune disorders, and genetic conditions. Navigating these regulations requires the regulatory landscape and strategic planning.
For companies seeking to capitalize on market opportunities and navigate challenges effectively, it is essential to stay informed of the latest regulatory trends and best practices. Additionally, collaboration with regulatory agencies and industry experts can help streamline the development process and bring products to market more efficiently. Overall, the market presents significant opportunities for growth, but companies must be prepared to navigate regulatory complexities and invest in innovation to stay competitive.

What will be the Size of the Biotech Market during the forecast period?

Request Free Sample

The market encompasses a dynamic and innovative industry focused on advancing biological systems through engineering, gene therapies, and tissue culturing. This sector is driving progress in various areas, including medicine, environmental sustainability, and agriculture. Notable applications include the development of treatments for conditions such as HIV, diabetes, obesity, neurological disorders, and transfyretin amyloidosis. Significant investments continue to fuel market growth, with innovative companies spearheading clinical success in areas like personalized medicine and regeneration technologies. Biotech is also making strides in the production of genetically modified crops, leading to improved plant varieties and increased agricultural efficiency. Government support and approval processes are crucial components of the market's growth trajectory.
Technological advancements, such as molecular breeding and cloning, are revolutionizing the way we approach challenges in healthcare and agriculture. The biotech industry's positive outcomes extend beyond the conventional plan, with potential solutions for societal issues like malaria and sedentary lifestyle-related diseases. Market revenue is expected to grow substantially as biotech continues to deliver breakthroughs in medicine, bio-pharmaceuticals, and bio-agriculture. The future of this sector is bright, as it continues to push the boundaries of science and technology to address some of the world's most pressing challenges.

How is this Biotech Industry segmented?

The biotech industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Biologics
  Therapeutics
  Diagnostics
  Industrial biotechnology
  Others


Type

  Red biotechnology
  White biotechnology
  Green biotechnology
  Grey biotechnology
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Sweden
    Switzerland
    UK


  Asia
  Rest of World (ROW)

By Product Insights

The biologics segment is estimated to witness significant growth during the forecast period. The market encompasses a range of product categories, with biologics emerging as a key and expanding segment. In August 2023, Novartis finalized its acquisition of Chinook Therapeutics, Inc., a Seattle, WA-based biopharmaceutical company specializing in precision medicines for kidney diseases. Valued at up to USD 3.5 billion, this acquisition underscores the strategic significance of biologics within the global biotech sector. Biotechnology advancements in areas like gene editing, proteomics, and genomics continue to fuel innovation in disease treatment and prevention.

Biotech startups and established biopharma companies alike invest heavily in research and development, driving medical breakthroughs and healthcare solutions. The biotech industry's focus on patient care, disease management, and pharmaceutical innovation is transforming healthcare trends and improving health outcomes. Biotechnology education, policy, and regulation play crucial roles in fostering a sustainable and ethical industry.

Get a

Snapshot img

Red Biotechnology Market Size 2025-2029

The red biotechnology market size is forecast to increase by USD 254.3 billion, at a CAGR of 7% between 2024 and 2029.

The market is experiencing significant growth, driven by the rapid advancements in genomic research and the increasing application of stem cell research and therapies. The potential of red biotechnology to revolutionize healthcare and agriculture is immense, with numerous opportunities for innovation and commercialization. However, the high development costs of red biotechnology methods pose a substantial challenge. These costs are attributed to the complex nature of the technologies involved, the need for specialized facilities and equipment, and the lengthy regulatory approval processes. Enhanced nutrient uptake and protein expression levels are also being explored through enzyme activity assays and root colonization efficacy studies.
Additionally, investing in research and development to reduce costs and improve efficiency will be crucial for long-term success. The market presents a compelling landscape for innovation and growth, with the potential to transform various industries and address pressing societal challenges. Companies that can navigate the challenges and capitalize on the opportunities will be well-positioned to lead in this dynamic and evolving market. Companies seeking to capitalize on the market opportunities must navigate these challenges effectively by collaborating with research institutions, securing strategic partnerships, and exploring cost-effective production methods. Tissue engineering and cell therapy are other key areas of focus, with clinical trials underway for chronic diseases like arthritis, type 2 diabetes, and TB.

What will be the Size of the Red Biotechnology Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

The market continues to evolve, driven by advancements in biosynthesis pathways and genetic engineering techniques. These innovations have led to the development of sustainable agri-inputs, such as pest resistance induction through metagenomic sequencing and the use of microbial inoculants. Water use efficiency and plant growth regulators are also gaining traction, with integrated pest management and plant-microbe interactions becoming key focus areas. One notable example of market activity is the 20% increase in nitrogen fixation rates observed in soybean crops through the application of phosphorus solubilizing microbial inoculants.
Humic acid fertilizers and fertilizer efficiency are gaining attention as potential solutions for improving crop stress tolerance and yield improvement ratios. Moreover, microbial community analysis and drought tolerance mechanisms are becoming essential components of precision agriculture tools. The industry is projected to grow at a robust rate, with expectations of a 15% annual expansion in the coming years.

How is this Red Biotechnology Industry segmented?

The red biotechnology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Monoclonal antibodies
  Gene therapy
  Polyclonal antibodies
  Cell-based immunotherapy products
  Others


End-user

  Pharmaceutical and biotechnology companies
  CMOs and CROs
  Academic research institutes


Diagnostic Methods

  Molecular diagnostics
  Immunoassays
  NGS


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Product Insights

The Monoclonal antibodies segment is estimated to witness significant growth during the forecast period. Monoclonal antibodies hold a significant position in the market, accounting for a substantial market share. According to recent industry reports, monoclonal antibody research and development experienced a growth of 18.7% in 2020. This expansion is attributed to factors such as the rising prevalence of chronic diseases, technological advancements, and the demand for personalized medicine. Monoclonal antibodies have made significant strides in therapeutic and diagnostic applications due to their ability to provide targeted therapy. The market is expected to grow by 15.3% in the upcoming years, with monoclonal antibodies continuing to play a pivotal role in this sector's advancements. This growth is driven by the increasing adoption of monoclonal antibodies in various industries, including healthcare and pharmaceuticals. Red biotechnology encompasses various cutting-edge technologies, including personalized precision medicine, CRISPR gene-editing technology, regenerative medicine, and bioprinting.

Monoclonal antibodies' unique properties make them indispen

This statistic shows the number of employees in the medical biotechnology industry in Germany from 2010 to 2023. In 2023, around ****** people were employed in medical biotechnology companies with a product on the market or that were developing a drug.

Base Year 2023 Forecast Period 2024-2028 Market Growth X.XX%*

Clinical Stage Biotechnology Market Outlook

The global clinical stage biotechnology market size is projected to witness significant growth from 2024 to 2032, driven by a robust CAGR of 12.4%. The market, valued at USD 34.5 billion in 2023, is expected to reach an impressive USD 98.4 billion by 2032. This growth is primarily fueled by advancements in biotechnology, increased investment in research and development, and the rising prevalence of chronic diseases that necessitate innovative therapeutic and diagnostic solutions.

One of the major growth factors of the clinical stage biotechnology market is the increasing prevalence of chronic and rare diseases, which has spurred the demand for advanced therapeutic solutions. For example, the rising cases of cancer, cardiovascular diseases, and neurodegenerative disorders have necessitated the development of novel biotechnological treatments that can address unmet medical needs. This has led to an increase in clinical trials, particularly in the oncology segment, where biotechnology companies are focusing on creating targeted therapies and personalized medicine.

Another significant driver is the continuous advancements in biotechnological research and development. Innovations such as CRISPR gene editing, CAR-T cell therapy, and monoclonal antibodies have revolutionized the treatment landscape. These cutting-edge technologies have not only improved the efficacy and safety profiles of treatments but have also opened new avenues for addressing diseases that were previously considered untreatable. The ability to manipulate biological systems at the molecular level has unlocked countless possibilities, driving the clinical stage biotechnology market forward.

Investment from both the public and private sectors plays a crucial role in propelling the market. Governments worldwide are committing substantial resources to biotechnology research, recognizing its potential to address critical health challenges. Additionally, venture capitalists and pharmaceutical giants are actively investing in promising biotech startups and companies, fostering an environment of innovation and rapid development. This influx of funds is enabling biotech firms to undertake ambitious research projects and bring new therapies to the market more quickly.

Regionally, North America holds the largest share in the clinical stage biotechnology market due to its well-established healthcare infrastructure, extensive research facilities, and supportive regulatory environment. Europe follows closely, with significant contributions from countries like Germany, the UK, and France. Meanwhile, the Asia Pacific region is anticipated to exhibit the highest growth rate, driven by increasing government investments in healthcare, a growing patient population, and rising awareness about biotechnological advancements. Latin America and the Middle East & Africa, though smaller in market size, are also witnessing gradual growth due to improving healthcare infrastructure and increased focus on biotechnology research.

Product Type Analysis

The clinical stage biotechnology market can be segmented by product type into therapeutics, diagnostics, vaccines, and others. The therapeutics segment constitutes the largest share due to the high demand for novel treatments for chronic and rare diseases. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, are at the forefront of this segment, providing targeted and effective treatments. Companies are increasingly focusing on developing therapies that offer better safety and efficacy profiles compared to traditional treatments.

Diagnostics is another rapidly growing segment, driven by the increasing need for early and accurate disease detection. Advances in molecular diagnostics, including next-generation sequencing, biomarker discovery, and liquid biopsies, have significantly enhanced the ability to diagnose diseases at an early stage. These technologies are not only improving patient outcomes but also reducing healthcare costs by enabling timely interventions. The growing emphasis on personalized medicine and companion diagnostics is further propelling this segment.

Vaccines represent a crucial segment within the clinical stage biotechnology market. The COVID-19 pandemic underscored the importance of rapid vaccine development and distribution, leading to unprecedented investments in vaccine research. Beyond COVID-19, there is a growing focus on developing vaccines for other infectious diseases and even some non-communicable diseases, such as certain ty

Snapshot img

Animal Biotechnology Market Size 2025-2029

The animal biotechnology market size is forecast to increase by USD 4.47 billion at a CAGR of 3.3% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing strategies of market players to expand their product portfolios and geographical reach. This trend is particularly evident in the development of innovative solutions for animal health and productivity. However, the market also faces challenges, including the increasing prevalence of animal diseases, which necessitate the need for more accurate and timely diagnostic tests. This presents an opportunity for companies to invest in research and development of advanced diagnostic tools and services. Despite this potential, the market growth is hindered by the lack of a skilled workforce capable of performing complex diagnostic tests. This labor shortage can be addressed through collaborations between academia, industry, and governments to train and educate the next generation of animal biotechnology professionals. Companies seeking to capitalize on market opportunities and navigate challenges effectively should focus on building a strong workforce, investing in research and development, and collaborating with industry partners to stay ahead of the competition. By doing so, they will be well-positioned to meet the growing demand for animal health solutions and contribute to the overall growth of the market.

What will be the Size of the Animal Biotechnology Market during the forecast period?

Request Free SampleThe market encompasses a range of applications, including genetic engineering for enhancing animal productivity, reproductive technologies, and the development of animal-based goods and derived products. This sector is driven by the growing demand for animal health solutions, as well as the potential for animal biotechnology in cancer treatment and pharmaceutical development. Public health systems and the animal feed sector also benefit from biotech solutions, such as disease resistance, therapeutic proteins, and diagnostic tests. Molecular biology plays a crucial role in advancing animal health through the identification and prevention of zoonotic diseases and the development of vaccines and drug treatments. Additionally, animal welfare and health management are key areas of focus, with biotech products and cloning techniques contributing to preventative care and protein synthesis. Overall, the market is experiencing significant growth, with ongoing research and innovation in areas such as disease treatment, vaccine development, and animal agriculture efficiency.

How is this Animal Biotechnology Industry segmented?

The animal biotechnology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. ProductDrugsVaccinesDiagnostic testsOthersAnimal TypeLivestock/productionCompanionTechnologyCRISPR-Cas9Gene transferGenome editingRNA interferenceNanotechnologyProduct TypeCloning servicesEmbryo biotechnologyGene editingIn vitro fertilization (IVF)Marker assisted selection (MAS)GeographyNorth AmericaUSCanadaEuropeFranceGermanyUKAsiaRest of World (ROW)

By Product Insights

The drugs segment is estimated to witness significant growth during the forecast period.Animal biotechnology encompasses various applications, including genetic composition, genetic engineering, reproductive technologies, animal health, animal-based goods, and animal-derived products. Genetic modification through techniques like electroporation method and random genomic integration is used to create genetically engineered animals with better nutritional profiles, disease resistance, and improved immunological responses. In vitro fertilization and genomic analytic tools are employed in clinical settings for genetic resources and diagnostics tests. Animal agriculture efficiency is enhanced through selective breeding and molecular biology, leading to improvements in cattle health, disease resistance, and the production of animal protein. Animal feed sector relies on feed additives and diagnostics tests for disease prevention and monitoring. Veterinary laboratories and point-of-care testing facilitate quick and accurate diagnosis of animal diseases, such as zoonotic diseases like foot and mouth disease (FMD), salmonella, swine fever, avian influenza, and bovine respiratory disease (BRD). Genetically modified organisms, including genetically altered transgenic animals, are used for cancer treatment, public health systems, and drug development. The use of these technologies in animal health and agriculture is crucial for maintaining animal welfare and ensuring food security.

Get a glance at the market report of share of various segments Request Free Sample

The Drugs segment was valued at USD 7.61

Germany Cell Counting Market was valued at USD 0.68 Billion in 2024 and is projected to reach USD 1.12 Billion by 2032, growing at a CAGR of 6.4% from 2026-2032.Advanced Diagnostic Requirements: Growing emphasis on precision diagnostics in German healthcare system drives demand for accurate cell counting technologies, supported by robust regulatory framework and quality standards.Biotech Sector Expansion: Significant growth in biotechnology and pharmaceutical companies across Germany creates sustained demand for sophisticated cell counting instruments for drug discovery and development processes.

The Germany Pharmaceutical Cdmo is projected to be valued at 10 billion euros in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 7%, reaching approximately 20 billion euros by 2034.

This statistic shows the distribution of revenues of biopharmaceutical companies compared to the total pharmaceutical market in Germany from 2007 to 2023. In 2023, the revenue of German biopharmaceutical companies amounted to **** billion euros, an increase compared to **** billion euros the year before.

Snapshot img

Marine Biotechnology Market Size 2025-2029

The marine biotechnology market size is forecast to increase by USD 5.53 billion at a CAGR of 10.5% between 2024 and 2029.

The market is experiencing significant growth, driven primarily by the increasing demand for sustainable biofuels and the urgent need to address climate change. This sector holds immense potential as marine organisms offer a rich source of bioactive compounds and renewable resources. However, the market is not without challenges. Legal and ethical issues surrounding the use of marine organisms and their genetic material remain a concern, necessitating stringent regulatory frameworks. Another trend in the market is the use of transgenic animals for producing recombinant proteins, which holds immense potential for the production of pharmaceuticals and industrial enzymes. Companies operating in this space must navigate these complexities to capitalize on the opportunities presented by this dynamic market. The trend towards developing eco-friendly technologies and products, coupled with advancements in genetic engineering and bioprospecting, is expected to fuel market growth.
Strategic partnerships, collaborations, and investments in research and development will be key to staying competitive in this evolving landscape. Companies seeking to capitalize on the opportunities in Marine Biotechnology must remain agile, innovative, and committed to sustainable practices to succeed in this market.

What will be the Size of the Marine Biotechnology Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of applications, from the exploration and utilization of marine bacteria and fungi for biofouling control and the production of bioactive peptides, lipids, and natural products, to the application of biotechnology tools such as high-throughput screening, synthetic biology, gene expression, and next-generation sequencing. This burgeoning industry also includes the development of bioprocess engineering and bioreactor design for the production of biocatalysts, as well as the implementation of bioremediation technologies for marine pollution control. Sustainable fisheries, marine ecosystem restoration, oceanographic modeling, and marine environmental monitoring are further areas of focus. Synthetic biology-enabled products, such as genome editing and marker-assisted breeding, further accelerate the development of new traits.
Additionally, marine biotechnology is exploring new frontiers in marine bioenergy, carbon sequestration, policy, ethics, and education. The market's growth is driven by the vast potential of the marine environment as a source of novel biological compounds and processes, as well as the increasing demand for sustainable and eco-friendly solutions to global challenges. For instance, vaccines and antibiotics are being developed using these technologies to improve animal health and productivity.

How is this Marine Biotechnology Industry segmented?

The marine biotechnology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Application

  Healthcare products
  Energy and environment management products
  Food and cosmetics products


Type

  Bio active substance
  Bio materials
  Others


Source

  Algae
  Marine fungi
  Corals and sponges
  Marine viruses
  Others


Technology

  Isolation and cultivation of microorganisms
  Culture-independent techniques


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Application Insights

The healthcare products segment is estimated to witness significant growth during the forecast period. Marine biotechnology is a dynamic and innovative field that offers significant potential for the discovery and development of new bioactive compounds. These compounds, derived from marine invertebrates, algae, and microorganisms, differ from their terrestrial counterparts and hold promise as novel medicines. For instance, marine-derived drugs include an antibiotic produced from fungi, two anti-cancer and herpes virus treatments from a sponge, and a painkiller from a snail that is 10,000 times more potent than morphine without its side effects. The marine invertebrate, Bugula neritina, is a potential source for a leukemia drug. Marine genomics, microbiology, and enzymology are key areas of research that contribute to the discovery of these bioactive compounds.

Furthermore, marine biotechnology has applications in sustainable aquaculture, bioremediation, biofuel production, and biomaterials. The industry is driven by advancements in gene editing, biotechnology platforms, and pharma

Germany Transfer Membrane Market was valued at USD 0.069 Billion in 2024 and is projected to reach USD 0.114 Billion by 2032, growing at a CAGR of 5.8% from 2026 to 2032.Biotechnology Research Excellence - Germany's position as Europe's largest biotechnology market with over 670 biotech companies and world-class research institutions like Max Planck Society and Helmholtz Association drives consistent demand for high-quality transfer membranes in protein analysis and molecular biology research.Pharmaceutical Industry Leadership - Germany's pharmaceutical sector, home to global leaders like Bayer and Boehringer Ingelheim, generates substantial demand for transfer membranes in drug development, quality control, and regulatory compliance testing across biologics and small molecule therapeutics.

Snapshot img

What is the Artificial Intelligence In Biotechnology Market Size?

The artificial intelligence in biotechnology market size is forecast to increase by USD 4.46 billion, at a CAGR of 19% between 2024 and 2029. Artificial Intelligence (AI) is revolutionizing the biotechnology industry by enhancing research and development processes, enabling accurate diagnoses, and improving productivity. Key growth factors fueling the market include substantial investments in biotechnology advancements and strategic collaborations between industry players and tech companies. However, the high initial cost of implementing AI solutions remains a challenge for smaller organizations. The market is expected to witness significant growth due to the increasing adoption of AI in areas such as drug discovery, genetic research, and agricultural technology. Furthermore, advancements in machine learning algorithms and natural language processing are enabling more precise and efficient data analysis, leading to new discoveries and innovations. Overall, the integration of AI in biotechnology is transforming the industry and offering numerous opportunities for growth.

What will be the size of the Market during the forecast period?

Request Free Artificial Intelligence In Biotechnology Market Sample

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.

Application

  Drug discovery and development
  Clinical trials and optimization
  Medical imaging
  Diagnostics
  Others


End-user

  Pharmaceutical companies
  Biotechnology companies
  Contract research organization (CRO)
  Healthcare providers
  Others


Geography

  North America

    US


  Europe

    Germany
    UK


  APAC

    China
    India
    Japan
    South Korea


  South America

    Brazil


  Middle East and Africa

Which is the largest segment driving market growth?

The drug discovery and development segment is estimated to witness significant growth during the forecast period. The market is experiencing significant growth, particularly in drug discovery and development. AI technologies are transforming the drug discovery process by increasing accuracy and efficiency in identifying potential drug candidates.

Get a glance at the market share of various regions. Download the PDF Sample

The drug discovery and development segment was valued at USD 522.60 million in 2019. AI applications in biotechnology extend beyond drug discovery, including compound screening, personalized medicine, and environmental factors analysis. This growth is driven by the increasing demand for personalized treatments, the need for faster drug development, and the potential for AI to revolutionize various applications in biotech and pharmaceuticals.

Which region is leading the market?

For more insights on the market share of various regions, Request Free Sample

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The North American region leads the global artificial intelligence (AI) market in biotechnology due to substantial investments, strategic collaborations, and technological advancements. With a strong infrastructure and a strong focus on innovation, the region is at the forefront of adopting and developing AI-driven biotechnological solutions. For example, in March 2023, Predictive Oncology partnered with Integra Therapeutics to enhance gene editing capabilities for cancer therapies. This collaboration leverages Predictive Oncology's expertise in protein expression to advance gene editing techniques, aiming to develop more effective cancer treatments. The partnership in Minnesota highlights the region's commitment to pioneering cancer research and therapeutic development through AI technology. In the life sciences sector, AI is utilized to analyze large datasets of genetic information, improve treatment outcomes, and increase productivity. Key players in the market include leading research institutions and biotechnology companies.

How do company ranking index and market positioning come to your aid?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abbott Laboratories - The company offers artificial intelligence in biotechnology solutions that include AI-driven medical imaging and predictive analytics for identifying individuals at risk of heart attacks.

Technavio provides the ranking index for the top 20 companies along with insights on the market

Germany Peptide Synthesis Market size is projected to reach USD $ 2.89 Billion by 2032, growing at a CAGR of 0.089% from 2026 to 2032.According to Verified Market Research, the following drivers and trends are shaping the Germany peptide synthesis market:Robust Pharmaceutical R&D Ecosystem:Germany's position as Europe's largest pharmaceutical market with companies like Bayer and Boehringer Ingelheim drives significant investment in peptide research and development. The country's strong intellectual property framework and regulatory expertise support innovation in peptide therapeutics, creating sustained demand for synthesis technologies and services.Government Support for Biotechnology Innovation: The German government's biotechnology strategy and funding initiatives, including the BioRegionen program, provide substantial support for peptide research projects.

This statistic depicts a selection of global top biotechnology companies based on market capitalization as of June 18, 2025. At this point, U.S. biopharmaceutical manufacturer Eli Lilly was ranked first among such companies, with a market capitalization of *** billion U.S. dollars. Thus, Eli Lilly was also the most valuable company of the whole biotech-pharma industry. Global biotechnologyAbbVie is among the largest, mostly biotech-oriented companies in the world. In June 2025, AbbVie, a company based in the U.S., had a market capitalization of *** billion U.S. dollars. As of 2020, there were ***** companies in the United States dedicated to biotechnology, while, in comparison, Germany had around *** such companies. Biotech companies located in the San Francisco Area and in Los Angeles/Orange County generate the highest amount of biotech revenue within the United States. In the United States, medical biotechnology is a significant component of the entire biotech industry. Jobs in research, testing, and medical laboratories have increased significantly. Biotechnology is also commonly used in agriculture. Biotech crops in the United States accounts for more than half of the world’s total. With a total of **** million acres of corn crops in the United States, only *** million acres are considered non-biotech fields. Biotechnology also extends into the industrial sector, providing innovation for nanotechnology, enzymes, and biofuels.